Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open ‐label extension of phase III randomized trials: Study 307

Epilepsia, EarlyView.

Source: Epilepsia - March 25, 2018 Category: Neurology Source Type: research